SYNTAX评分II 2020的外部验证
该研究在日本PCI/CABG注册队列的7362例三支病变和/或左主干病变患者中外部验证了SYNTAX评分II 2020(SSII-2020)对5年死亡和MACE的预测能力,并评估其指导血运重建方式选择的价值。结果显示SSII-2020对5年死亡预测良好(C指数=0.72),且按预测绝对风险差分组后,低风险差组PCI与CABG的观察死亡率无显著差异,高风险差组CABG生存获益显著;但对MACE的预测不足以推荐特定治疗。
要点
- SSII-2020对5年死亡预测良好,C指数=0.72,校准截距-0.11、斜率0.92。
- 预测5年死亡绝对风险差<4.5%时,PCI与CABG观察死亡率无显著差异(观察ARD 2.1%)。
- 预测5年死亡绝对风险差≥4.5%时,CABG生存获益显著(观察ARD 9.7%)。
核心结论
- SSII-2020预测5年死亡的能力可支持三支病变和/或左主干病变患者的血运重建决策。
- SSII-2020对MACE的预测不足以准确推荐特定治疗方式。
研究设计与样本
- 研究为外部验证,纳入日本PCI/CABG注册队列中7362例三支病变和/或左主干病变患者。
- 评估SSII-2020对5年死亡和MACE的区分度(Harrell C统计量)及校准度。
主要发现
- SSII-2020预测5年死亡的C指数=0.72,校准截距=-0.11,斜率=0.92。
- 预测5年死亡绝对风险差<4.5%组,PCI与CABG观察死亡率无显著差异,观察ARD为2.1%(95%CI:-0.4%至4.4%)。
- 预测5年死亡绝对风险差≥4.5%组,CABG生存获益显著,观察ARD为9.7%(95%CI:6.1%至13.3%)。
关键数值与推荐
- 预测5年死亡绝对风险差<4.5%视为PCI与CABG等效。
- 预测5年死亡绝对风险差≥4.5%视为CABG更优。
临床怎么用
- 对于三支病变和/或左主干病变患者,可用SSII-2020预测5年死亡风险辅助选择PCI或CABG。
- SSII-2020预测的绝对风险差可用于识别可能从CABG生存获益更多的高危患者。
- 不推荐仅依据SSII-2020预测MACE来选择血运重建方式。
局限性
- 研究为非随机注册队列,可能存在选择偏倚。
- 结论基于日本人群,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SYNTAX score II 2020 (SSII-2020) was derived from cross correlation and externally validated in randomized trials to predict death and major adverse cardiac and cerebrovascular events (MACE) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in patients with 3-vessel disease (3VD) and/or left main coronary artery disease (LMCAD). OBJECTIVES: The authors aimed to investigate the SSII-2020's value in identifying the safest modality of revascularization in a non-randomized setting. METHODS: Five-year mortality and MACE were assessed in 7,362 patients with 3VD and/or LMCAD enrolled in a Japanese PCI/CABG registry. The discriminative abilities of the SSII-2020 were assessed using Harrell's C statistic. Agreement between observed and predicted event rates following PCI or CABG and treatment benefit (absolute risk difference [ARD]) for these outcomes were assessed by calibration plots. RESULTS: The SSII-2020 for 5-year mortality well predicted the prognosis after PCI and CABG (C-index = 0.72, intercept = -0.11, slope = 0.92). When patients were grouped according to the predicted 5-year mortality ARD, <4.5% (equipoise of PCI and CABG) and ≥4.5% (CABG better), the observed mortality rates after PCI and CABG were not significantly different in patients with lower predicted ARD (observed ARD: 2.1% [95% CI: -0.4% to 4.4%]), and the significant difference in survival in favor of CABG was observed in patients with higher predicted ARD (observed ARD: 9.7% [95% CI: 6.1%-13.3%]). For MACE, the SSII-2020 could not recommend a specific treatment with sufficient accuracy. CONCLUSIONS: The SSII-2020 for predicting 5-year death has the potential to support decision making on revascularization in patients with 3VD and/or LMCAD.
引用
- Hara H, Shiomi H, van Klaveren D, et al. External Validation of the SYNTAX Score II 2020. J Am Coll Cardiol. 2021. PMID: 34531023. doi:10.1016/j.jacc.2021.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。